Link to this page
Physician Data Query
| Preferred Name | alemtuzumab | |
| Synonyms |
Monoclonal Antibody Campath-1H MabCampath Monoclonal Antibody CD52 Campath Campath-1H anti-CD52 monoclonal antibody MoAb CD52 |
|
| Definitions |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1681" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1681" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000037783 |
|
| altLabel |
Monoclonal Antibody Campath-1H MabCampath Monoclonal Antibody CD52 Campath Campath-1H anti-CD52 monoclonal antibody MoAb CD52
|
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000365542 http://purl.bioontology.org/ontology/PDQ/CDR0000257897 http://purl.bioontology.org/ontology/PDQ/CDR0000420822 http://purl.bioontology.org/ontology/PDQ/CDR0000355733 http://purl.bioontology.org/ontology/PDQ/CDR0000340973 http://purl.bioontology.org/ontology/PDQ/CDR0000380935 http://purl.bioontology.org/ontology/PDQ/CDR0000429484 http://purl.bioontology.org/ontology/PDQ/CDR0000038585 |
|
| cui |
C1178562 C0939276 C0383429 C1271482
|
|
| Date last modified |
2006-07-26
|
|
| definition |
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1681" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1681" NCI Thesaurus)
|
|
| IND Code |
10864
|
|
| Legacy PDQ ID |
10139
|
|
| LT |
TRD
|
|
| NCI ID |
C1681
|
|
| notation |
CDR0000037783
|
|
| NSC Code |
715969
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
alemtuzumab
|
|
| tui |
T109 T116 T129 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |